ProfileGDS5678 / 1448603_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 85% 82% 83% 89% 87% 85% 85% 85% 85% 84% 84% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3492285
GSM967853U87-EV human glioblastoma xenograft - Control 26.3453985
GSM967854U87-EV human glioblastoma xenograft - Control 36.3456585
GSM967855U87-EV human glioblastoma xenograft - Control 46.1601582
GSM967856U87-EV human glioblastoma xenograft - Control 56.1762983
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7161989
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5117787
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3267585
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3307385
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3594785
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3357285
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3282284
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1844584
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.346785